PTGS2 and Alzheimer disease: Moreover, due to known adverse cardiovascular eventswith chronic use of COX2 drugs,70−73 there is little to no incentive or enthusiasm toconduct additional long-term clinical trials with COX2 drugs for debilitatingdiseases such as AD,75 post-traumatic epilepsy,or other chronic neurodegenerative diseases.